The Function of Host-derived Extracellular Vesicles in Trafficking of Bacterial Antigens to Stimulate the Antibacterial Immune Response
宿主来源的细胞外囊泡在细菌抗原运输中刺激抗菌免疫反应的功能
基本信息
- 批准号:10609082
- 负责人:
- 金额:$ 45.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-12 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvanced DevelopmentAffectAnimalsAnti-Bacterial AgentsAntibodiesAntigen PresentationAntigen-Presenting CellsAntigensAutophagocytosisBacteriaBacterial AntigensBacterial InfectionsBone MarrowCD4 Positive T LymphocytesCell CommunicationCell physiologyCellsCellular ImmunityCessation of lifeCommunicationDataDendritic CellsDevelopmentEndosomesFecesFood ContaminationFutureGastroenteritisGoalsHost DefenseHumanHumoral ImmunitiesITGAM geneImmuneImmune responseImmune signalingImmune systemImmunityInfectionInfiltrationIntranasal AdministrationKnowledgeLeadLicensingLifeMacrophageMediatingMissionModelingMucous MembraneMulti-Drug ResistanceMusMycobacterium tuberculosisNational Institute of Allergy and Infectious DiseaseNatural ImmunityOutcomePathogenicityPathway interactionsPhenotypePreventive measureProcessProductionProteinsPublic HealthPublishingRNAResearchRoleSalmonellaSalmonella entericaSalmonella infectionsSalmonella typhimuriumSepticemiaSubunit VaccinesT-Cell ActivationT-LymphocyteTh1 CellsTherapeuticVaccine DesignVaccinesVesicleWater consumptionWorkacid fast bacteriaadaptive immune responseadaptive immunitycontaminated watercytokinedesignexosomeextracellular vesiclesin vivoinnovationintercellular communicationlymph nodesmigrationmouse modelnanoscalenovelpathogenrecruitresponsetraffickingtransmission process
项目摘要
There is no licensed vaccine for humans against potentially life-threatening paratyphoid and nontyphoidal
septicemia caused by the Salmonella enterica. This intracellular pathogen evades sophisticated host immune
defenses. The host immune system is controlled by regulatory mechanisms, such as intercellular communication
between infected and uninfected cells, which can also be accomplished via small extracellular vesicles (EVs),
exosomes. Exosomes are vesicles that originate in the endosomal pathway and transport cargo to other cells.
We found that exosomes carry bacterial antigens (Ags) from S. Typhimurium-infected macrophages (
MΦ
s) and
stimulate naïve antigen-presenting cells involved in T cell recruitment, and an intranasal administration of these
exosomes leads to the production of anti-S. Typhimurium antibodies (Abs) and stimulation of Th 1 response
critical for engulfing and killing intracellular bacteria. These adaptive responses are Ags-dependent, but the Ags
responsible for this humoral response or the mechanisms responsible for Ag trafficking to EVs are unknown. We
will address the contribution of exosomes to adaptive immune responses against intracellular pathogens as there
is a critical need to determine new mechanisms of protective immune responses, such as exosome-modulated
immunity. Our long-term goal is to advance the development of mechanism-based preventative measures for
bacterial infections. Our overall objective is to elucidate the mechanisms whereby bacterial Ags are trafficked to
exosomes and identify the capability of exosomes to generate protective cellular and humoral immunity against
intracellular Salmonella. Our central hypothesis is that Salmonella Ags are trafficked to endosomal
compartments of infected MΦs and released via exosomes to stimulate innate responses and Ag-specific
Th1
cell responses
. The rationale is that determining the mechanisms via which Salmonella Ags are trafficked to
exosomes and generate adaptive immunity against Salmonella, we will assign a novel role of EVs in host
defense, important for the design of preventative approaches. In Aim 1, we will identify mechanisms whereby
Salmonella Ags are trafficked into EVs. In Aim 2, we will determine the mechanisms by which EVs produced by
Salmonella-infected
determine how EVs
MΦ
s regulate the activation and function of DCs in mucosal tissues. In Aim 3, we will
derived from Salmonella-infected
MΦ
s drive adaptive immunity. The expected outcomes
are that we will have established a mechanism responsible for the trafficking of Ags into EVs, and characterize
novel roles of EVs in innate immunity and Th1 adaptive immunity. This study will have a positive impact as it will
provide a conceptual framework for the future development of targets for vaccine design and significantly
advance knowledge of how Salmonella disrupts host immunity, which is vital for the development of preventative
and therapeutic approaches against this pathogen. The innovation lies in addressing the function of EVs
produced by host cells in rendering protection against salmonellosis. This study is significant since we will
advance knowledge on the function of host exosomes in altering the immune response to Salmonella infection.
目前还没有针对可能危及生命的副伤寒和非伤寒的许可疫苗
由沙门氏菌引起的败血症。这种细胞内病原体逃避复杂的宿主免疫
的防御合作.宿主免疫系统受调节机制控制,如细胞间通讯
感染和未感染的细胞之间,这也可以通过小的细胞外囊泡(EV)来实现,
外来体外泌体是起源于内体途径并将货物运输到其他细胞的囊泡。
我们发现外泌体携带来自S.伤寒沙门氏菌感染的巨噬细胞(
MΦ
s)和
刺激参与T细胞募集的幼稚抗原呈递细胞,以及鼻内施用这些抗原呈递细胞。
外泌体导致抗S抗体的产生。鼠伤寒抗体(Abs)和刺激Th 1应答
对吞噬和杀死细胞内细菌至关重要。这些适应性反应是依赖于Ags的,但Ags
负责这种体液反应或负责Ag运输到EV的机制尚不清楚。我们
将解决外泌体对细胞内病原体的适应性免疫反应的贡献,
目前迫切需要确定保护性免疫反应的新机制,例如外泌体调节的
免疫力我们的长期目标是推进基于机制的预防措施的发展,
细菌感染我们的总体目标是阐明细菌抗原被运输到
外泌体,并鉴定外泌体产生保护性细胞和体液免疫的能力,
胞内沙门氏菌我们的中心假设是沙门氏菌抗原被运输到内体,
感染的MΦ的隔室,并通过外泌体释放,以刺激先天性反应和Ag特异性免疫反应。
Th1
细胞应答
.其基本原理是,确定沙门氏菌抗原被贩运到
外泌体并产生针对沙门氏菌的适应性免疫,我们将赋予EV在宿主中的新作用
防御,对预防方法的设计很重要。在目标1中,我们将确定
沙门氏菌Ag被贩运到电动汽车中。在目标2中,我们将确定通过以下方式产生EV的机制:
沙门氏菌感染
确定电动汽车如何
MΦ
s调节粘膜组织中DC的活化和功能。在目标3中,我们
来源于沙门氏菌感染
MΦ
s驱动适应性免疫。预期成果
我们将建立一个机制,负责将Ag贩运到EV中,并描述
EV在先天免疫和Th1适应性免疫中的新作用。这项研究将产生积极的影响,因为它将
为疫苗设计的目标的未来发展提供了一个概念框架,
沙门氏菌如何破坏宿主免疫力的先进知识,这对于预防性药物的开发至关重要。
以及针对这种病原体的治疗方法。创新在于解决电动汽车的功能
由宿主细胞产生以提供对沙门氏菌病的保护。这项研究意义重大,因为我们将
进一步了解宿主外泌体在改变对沙门氏菌感染的免疫反应中的功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mariola Jadwiga Ferraro其他文献
Mariola Jadwiga Ferraro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mariola Jadwiga Ferraro', 18)}}的其他基金
The Function of Host-derived Extracellular Vesicles in Trafficking of Bacterial Antigens to Stimulate the Antibacterial Immune Response
宿主来源的细胞外囊泡在细菌抗原运输中刺激抗菌免疫反应的功能
- 批准号:
10443148 - 财政年份:2022
- 资助金额:
$ 45.18万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 45.18万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 45.18万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 45.18万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 45.18万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 45.18万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 45.18万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 45.18万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 45.18万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 45.18万 - 项目类别:














{{item.name}}会员




